- Home
- CNTA vs MGNI Comparison
CNTA vs MGNI Comparison
Compare CNTA & MGNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- MGNI
- Stock Information
- Founded
- CNTA 2020
- MGNI 2007
- Country
- CNTA United Kingdom
- MGNI United States
- Employees
- CNTA N/A
- MGNI N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- MGNI Computer Software: Programming Data Processing
- Sector
- CNTA Health Care
- MGNI Technology
- Exchange
- CNTA Nasdaq
- MGNI Nasdaq
- Market Cap
- CNTA 2.3B
- MGNI 2.5B
- IPO Year
- CNTA 2021
- MGNI N/A
- Fundamental
- Price
- CNTA $16.46
- MGNI $15.72
- Analyst Decision
- CNTA Strong Buy
- MGNI Strong Buy
- Analyst Count
- CNTA 8
- MGNI 14
- Target Price
- CNTA $23.71
- MGNI $18.39
- AVG Volume (30 Days)
- CNTA 470.8K
- MGNI 1.5M
- Earning Date
- CNTA 11-12-2024
- MGNI 02-26-2025
- Dividend Yield
- CNTA N/A
- MGNI N/A
- EPS Growth
- CNTA N/A
- MGNI N/A
- EPS
- CNTA N/A
- MGNI 0.12
- Revenue
- CNTA $6,853,000.00
- MGNI $661,134,000.00
- Revenue This Year
- CNTA N/A
- MGNI $0.60
- Revenue Next Year
- CNTA N/A
- MGNI $10.37
- P/E Ratio
- CNTA N/A
- MGNI $132.02
- Revenue Growth
- CNTA N/A
- MGNI 8.71
- 52 Week Low
- CNTA $7.38
- MGNI $8.38
- 52 Week High
- CNTA $18.97
- MGNI $18.38
- Technical
- Relative Strength Index (RSI)
- CNTA 50.86
- MGNI 46.71
- Support Level
- CNTA $14.61
- MGNI $14.89
- Resistance Level
- CNTA $17.65
- MGNI $16.44
- Average True Range (ATR)
- CNTA 1.08
- MGNI 0.65
- MACD
- CNTA -0.10
- MGNI -0.13
- Stochastic Oscillator
- CNTA 56.74
- MGNI 30.97
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About MGNI Magnite Inc.
Magnite is one of the largest supply-side platform providers, or SSP, in online advertising. The firm was previously named The Rubicon Project (an online ad exchange) and became Magnite after merging with Telaria (an SSP focused mainly on streaming video providers) in 2020. The firm also purchased another of the leading SSPs within the CTV market, SpotX, in 2021 for $1.2 billion, cementing its long-term focus on grabbing market share in this area. The firm generates nearly 45% of its revenue from the programmatic sale of CTV ad inventory, 35% from mobile online sites and apps, and the remaining from websites accessed via computer.